Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Capucine Baldini

Showing results (51-60 of 101) with videos related to

Pageof 11
Sort By:
Annals of the Rheumatic Diseases|June 3, 2018
Drug-induced lupus erythematosus following immunotherapy with anti-programmed death-(ligand) 1Jean-Marie Michot, Mathilde Fusellier, Stephane Champiat, et al.
Cancer Drug Resistance (Alhambra, Calif.)|May 18, 2022
Clinical significance of the loss of CD20 antigen on tumor cells in patients with relapsed or refractory follicular lymphomaJean-Marie Michot, Alice Buet-Elfassy, Maxime Annereau, et al.
Nutrients|March 29, 2023
Prevalence of Four Sarcopenia Criteria in Older Patients with Cancer, and Their Predictive Value for 6-Month Mortality: The NutriAgeCancer National Prospective Cohort StudyClaudia Martinez-Tapia, Kevin Rougette, Virginie Fossey-Diaz, et al.
European Journal of Cancer (Oxford, England : 1990)|June 3, 2018
Organisational factors influencing early clinical trials enrollment: Gustave Roussy experienceSylvain Besle, Emilien Schultz, Antoine Hollebecque, et al.
European Journal of Haematology|September 21, 2024
Relevance, Risks, and Benefits of Early-Phases Clinical Trials Participations for Patients With Hematological Malignancies From 2008 to 2023Matteo Guerra, Emily Alouani, Thomas Hueso, et al.
Bulletin Du Cancer|January 1, 2019
Capucine Baldini, Patricia Martin Romano, Andreea Varga, et al.
Cancer Immunology, Immunotherapy : CII|July 24, 2020
Patterns of progression in patients treated for immuno-oncology antibodies combinationAlice Bernard-Tessier, Capucine Baldini, Eduardo Castanon, et al.
Cancer|June 19, 2025
First-in-human phase 1 study of KHK2455 monotherapy and in combination with mogamulizumab in patients with advanced solid tumorsTimothy A Yap, Olivier Rixe, Capucine Baldini, et al.
Cancer Treatment Reviews|May 10, 2024
Toxicity of immunotherapy combinations with chemotherapy across tumor indications: Current knowledge and practical recommendationsLayal Rached, Ariane Laparra, Madona Sakkal, et al.
European Journal of Cancer (Oxford, England : 1990)|September 25, 2023
Immunosuppressant mycophenolate mofetil for patients with steroid-refractory immune-related hepatitis induced by checkpoint inhibitors in oncologyEmily Alouani, Ariane Laparra, Audrey Perret, et al.
Pageof 11

Showing results (51-60 of 101) with videos related to

Sort By:
Pageof 11
Annals of the Rheumatic Diseases|June 3, 2018
Drug-induced lupus erythematosus following immunotherapy with anti-programmed death-(ligand) 1Jean-Marie Michot, Mathilde Fusellier, Stephane Champiat, et al.
Cancer Drug Resistance (Alhambra, Calif.)|May 18, 2022
Clinical significance of the loss of CD20 antigen on tumor cells in patients with relapsed or refractory follicular lymphomaJean-Marie Michot, Alice Buet-Elfassy, Maxime Annereau, et al.
Nutrients|March 29, 2023
Prevalence of Four Sarcopenia Criteria in Older Patients with Cancer, and Their Predictive Value for 6-Month Mortality: The NutriAgeCancer National Prospective Cohort StudyClaudia Martinez-Tapia, Kevin Rougette, Virginie Fossey-Diaz, et al.
European Journal of Cancer (Oxford, England : 1990)|June 3, 2018
Organisational factors influencing early clinical trials enrollment: Gustave Roussy experienceSylvain Besle, Emilien Schultz, Antoine Hollebecque, et al.
European Journal of Haematology|September 21, 2024
Relevance, Risks, and Benefits of Early-Phases Clinical Trials Participations for Patients With Hematological Malignancies From 2008 to 2023Matteo Guerra, Emily Alouani, Thomas Hueso, et al.
Bulletin Du Cancer|January 1, 2019
Capucine Baldini, Patricia Martin Romano, Andreea Varga, et al.
Cancer Immunology, Immunotherapy : CII|July 24, 2020
Patterns of progression in patients treated for immuno-oncology antibodies combinationAlice Bernard-Tessier, Capucine Baldini, Eduardo Castanon, et al.
Cancer|June 19, 2025
First-in-human phase 1 study of KHK2455 monotherapy and in combination with mogamulizumab in patients with advanced solid tumorsTimothy A Yap, Olivier Rixe, Capucine Baldini, et al.
Cancer Treatment Reviews|May 10, 2024
Toxicity of immunotherapy combinations with chemotherapy across tumor indications: Current knowledge and practical recommendationsLayal Rached, Ariane Laparra, Madona Sakkal, et al.
European Journal of Cancer (Oxford, England : 1990)|September 25, 2023
Immunosuppressant mycophenolate mofetil for patients with steroid-refractory immune-related hepatitis induced by checkpoint inhibitors in oncologyEmily Alouani, Ariane Laparra, Audrey Perret, et al.
Pageof 11